A multidimensional index and staging system for idiopathic pulmonary fibrosis.

TitleA multidimensional index and staging system for idiopathic pulmonary fibrosis.
Publication TypeJournal Article
Year of Publication2012
AuthorsLey, B, Ryerson, CJ, Vittinghoff, E, Ryu, JH, Tomassetti, S, Lee, JS, Poletti, V, Buccioli, M, Elicker, BM, Jones, KD, King, TE, Collard, HR
JournalAnn Intern Med
Date Published2012 May 15
KeywordsAge Factors, Female, Humans, Idiopathic Pulmonary Fibrosis, Lung, Lung Transplantation, Male, Middle Aged, Models, Statistical, Prognosis, Pulmonary Diffusing Capacity, Retrospective Studies, Risk Assessment, Vital Capacity

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research.OBJECTIVE: To develop a multidimensional prognostic staging system for IPF by using commonly measured clinical and physiologic variables.DESIGN: A clinical prediction model was developed and validated by using retrospective data from 3 large, geographically distinct cohorts.SETTING: Interstitial lung disease referral centers in California, Minnesota, and Italy.PATIENTS: 228 patients with IPF at the University of California, San Francisco (derivation cohort), and 330 patients at the Mayo Clinic and Morgagni-Pierantoni Hospital (validation cohort).MEASUREMENTS: The primary outcome was mortality, treating transplantation as a competing risk. Model discrimination was assessed by the c-index, and calibration was assessed by comparing predicted and observed cumulative mortality at 1, 2, and 3 years.RESULTS: Four variables were included in the final model: gender (G), age (A), and 2 lung physiology variables (P) (FVC and Dlco). A model using continuous predictors (GAP calculator) and a simple point-scoring system (GAP index) performed similarly in derivation (c-index of 70.8 and 69.3, respectively) and validation (c-index of 69.1 and 68.7, respectively). Three stages (stages I, II, and III) were identified based on the GAP index with 1-year mortality of 6%, 16%, and 39%, respectively. The GAP models performed similarly in pooled follow-up visits (c-index ≥71.9).LIMITATION: Patients were drawn from academic centers and analyzed retrospectively.CONCLUSION: The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF.

Alternate JournalAnn. Intern. Med.
PubMed ID22586007
Grant ListHL086516 / HL / NHLBI NIH HHS / United States